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We evaluated temporal fluctuations in macrolide resistance rates, analysing genetic
determinants of resistance and clonal evolution in a population of 2744 S. pyogenes isolates
collected in the period 2000–2013. The total resistance rate to erythromycin of the isolates was
17.9 %. A maximum of erythromycin resistance emerged in 2000 (38.6 %), followed by a
significant decrease to 5.2 % in 2012 (P,0.0001). Molecular analysis revealed the presence
and co-presence of known genetic resistance determinants mefA, mefE, ermTR and ermB, in
line with phenotypes. PFGE analysis identified genetically related groups in 2000 and 2007–
2008, mainly the MLS and M phenotypes, respectively. The most prevalent emm types among a
representative subset of resistant isolates were emm2, emm75 and emm77. All emm2 and
88.2 % of the strains harbouring the emm75 gene were only recorded in M-phenotype strains,
whilst all emm77-positive strains had the inducible MLS phenotype. The analysed susceptible
isolates showed several emm types partially shared with resistant ones. Our results suggest that
changes in bacterial population clonality, rather than horizontal transfer of resistance
determinants, plays a major epidemiological role in S. pyogenes. Continuous monitoring of
microbiological epidemiology seems to be crucial for correct and effective management of
streptococcal infections.
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INTRODUCTION
Streptococcus pyogenes is a major human Gram-positive
pathogen that causes a wide range of invasive and non-
invasive infections, suppurative complications and non-
suppurative sequelae, including acute rheumatic fever and
acute glomerulonephritis (Bisno & Stevens, 2007). Its sus-
ceptibility to penicillin remains stable, despite many years
of exposure; penicillin is therefore the universally rec-
ommended treatment for S. pyogenes infections. Erythro-
mycin and related antibiotics are the main alternatives in
patients with penicillin allergy (Shulman et al., 2012).
Despite their limited indication for anti-streptococcal
therapy, macrolides have often been employed as empirical
therapy for respiratory tract infections due to their broad
spectrum and low toxicity, in addition to their favourable
pharmacokinetic and pharmacodynamic parameters
(Bisno et al., 2002; Horn et al., 1998). However, streptococ-
cal resistance to macrolides and lincosamides emerged and
spread worldwide until 2000 (Bingen et al., 2000; Grivea
et al., 2006; Pe´rez-Trallero et al., 2007). Interestingly,
recent reports reveal a worldwide decrease in resistance
(d’Humie`res et al., 2012; Huang et al., 2014; Montes
et al., 2014).
Macrolide resistance in S. pyogenes is caused by two main
mechanisms: (i) an efflux system encoded by mef-class
genes (M phenotype), and (ii) a target site modification
encoded by erm-class genes (MLS phenotype). The M phe-
notype is associated with low-level resistance to 14- and 15-
membered macrolides, whereas the MLS phenotype is
associated with high-level resistance, which may be consti-
tutive (cMLS) or inducible (iMLS) (Seppa¨la¨ et al., 1998;
Sutcliffe et al., 1996).
Understanding the epidemiology of S. pyogenes resistance
could be useful for correct management of streptococcal
infections through appropriate therapeutic approaches
(Lamagni et al., 2008), but data on macrolide resistance
3These authors contributed equally to this work.
Abbreviations: CLSI, Clinical Laboratory Standards Institute; UPGMA,
unweighted pair group method with arithmetic mean.
One supplementary figure is available with the online Supplementary
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rates in different European countries are still lacking. Here,
we report an epidemiological and molecular study of
macrolide susceptibility patterns of S. pyogenes isolates
from an area in central Italy over a 14-year period. Our
aim was to evaluate temporal fluctuations, genetic determi-
nants and clonal evolution of macrolide resistance of
S. pyogenes isolated in this period.
METHODS
Bacterial strains. Non-repetitive S. pyogenes strains (n52744) were
isolated from paediatric and adult patients at the Infectious Diseases
Unit, Department of Medical Biotechnologies, University of Siena,
Italy, from January 2000 to December 2013. They were recovered
from respiratory, skin, conjuctival, genitourinary and blood sources.
Isolates from sterile sites (e.g. blood) were considered invasive. All
strains were community acquired, as they were isolated from out-
patients or inpatients within 48 h of hospital admission. Bacterial
isolation and identification were performed by standard procedures
(Ruoff, 2003). Briefly, isolates were identified by colony morphology,
b-haemolysis on sheep blood agar and commercial latex agglutination
test (Streptococcal Grouping kit; Oxoid). Bacterial strains were pre-
served in Wilkins–Chalgren broth with 20 % glycerol at 280 uC until
further analysis.
Antibiotic susceptibility tests. In vitro susceptibility to macrolides
and lincosamides was tested in all 2744 isolates. Assays were per-
formed and the results were interpreted according to Clinical Lab-
oratory Standards Institute (CLSI) indications (CLSI, 2012).
Susceptibility to 14- and 16-membered ring macrolides (ery-
thromycin, spiramycin) and to lincosamides (clindamycin) was
determined by the Kirby–Bauer disk diffusion method on Mueller–
Hinton agar with 5 % sheep blood plates (Oxoid/Thermo Scientific).
Apart from the CLSI double disk indication, a triple-disk diffusion
test was performed to discriminate M, cMLS and iMLS, so as to
highlight any heterogeneity of inducible resistance, as described pre-
viously (Giovanetti et al., 1999).
Genetic analysis. Erythromycin-resistant bacterial strains were
clustered in four main representative sample groups according to
resistance percentage fluctuations, including all erythromycin-resist-
ant isolates. These were: (i) the year 2000 (n576); (ii) 2002–2003
(n5124); (iii) 2007–2008 (n557) and (iv) 2009 (n58). The presence
of erm and mef resistance determinants was evaluated by PCR in total
clustered isolates (n5265). For technical reasons, it was not possible
to obtain PFGE profiles for 54 erythromycin-resistant strains.
A sample of 24 susceptible isolates also underwent the same PFGE and
PCR analysis.
A previous study found that if two isolates belonged to the same
PFGE cluster, they were likely to have the same emm sequence type
(Carric¸o et al., 2006). On this basis, we performed emm typing on a
subset of 29 macrolide-resistant isolates (19 M phenotypes and 10
MLS phenotypes): one isolate representative of each distinct PFGE
clone was selected in the case of more than one isolate, and when
clones included isolates from different years, one isolate per year was
also selected. Four resistant isolates grouped into two clones from
2003 were no longer available at the time of the emm typing pro-
cedures. For emm typing, the same sampling criteria were applied to
obtain a representative subset of susceptible PFGE clones. We also
added three susceptible isolates that were clonally related to macro-
lide-resistant ones (total n514).
Genomic DNA extraction and PCR. Total genomic bacterial DNA
employed as template for PCRs was obtained by boiling the bacterial
cells, as described in the CDC protocol (http://www.cdc.gov/streplab/
protocol-emm-type.html). The genomic DNA was immediately used
as template for PCRs or stored at 220 uC for subsequent studies.
In order to amplify the erm and mef genes, primer pairs were designed
as described previously (Cresti et al., 2002). PCR products were
analysed by agarose gel electrophoresis and ethidium bromide
staining.
PFGE. Bacterial DNA was digested with Cfr9I (Fermentas), shown in
previous studies to act on Sma I-resistant DNA (Bacciaglia et al.,
2007). Macrorestriction profile analysis was performed using dedi-
cated software (Diversity Database, version 2.2.0; Bio-Rad) that
generated unweighted pair group method with arithmetic mean
(UPGMA) dendrograms, applying the band-based Dice similarity
coefficient, with optimization and position tolerance settings of 1.0
and 1.5, respectively. The dendrograms revealed a PFGE cluster when
a group of isolates had i80 % similarity (Sneath & Sokal, 1973; van
Belkum et al., 2007). For epidemiological purposes, clonal relation-
ships between isolates were defined according to Tenover criteria
(Tenover et al., 1995): groups of isolates that were (i) genetically
undistinguishable when they had the same restriction profile, or (ii)
closely genetically related when they differed by fewer than four
restriction fragments, were considered clones.
emm typing. emm typing was carried out according to CDC
guidelines (http://www.cdc.gov/streplab/protocol-emm-type.html).
Enzymic extraction of streptococcal genomic DNA was replaced by
bacterial boiling in distilled water (Tewodros & Kronvall, 2005) and
PCR amplification of the emm gene was carried out by the CDC
protocol and PCR product sequencing. Sequenced PCR products
were then compared with the CDC database to retrieve the emm type.
Statistical analysis. Statistical analysis was performed using CDC
EpiInfo (http://www.cdc.gov/epiinfo). Categorical variables were
compared by a x 2 test or, when appropriate, Fisher’s exact test. A x 2
test for trend was used to evaluate temporal variations. A P value of
v0.05 was considered statistically significant.
RESULTS
Macrolide resistance rates
Out of 2744 strains, 2646 (96.5 %) were isolated from the
respiratory tract, mostly from nasal and pharyngeal
swabs; 94 (3.4 %) were isolated from skin, conjunctiva or
the genitourinary tract; and four strains (0.1 %) were iso-
lated from blood and therefore considered invasive.
A total of 491 (17.9 %) erythromycin-resistant isolates
were identified in the 14-year collection period. M and
MLS phenotypes showed a similar distribution: 238
(8.7 %) and 253 (9.2 %) isolates, respectively.
The year-by-year temporal variations in erythromycin
resistance and phenotype percentages are shown in Fig. 1.
There was a significant decrease in erythromycin resistance
from 38.6 % of the isolates in 2000 to 10.7 % in 2013
(Pv0.0001). The overall decreasing trend was also signifi-
cant for the single phenotypes (Pv0.0001), but compari-
son of the years 2000 and 2013 highlighted a significant
decrease in MLS isolates (30.4 vs 7.8 %, Pv0.0001) associ-
ated with a non-statistically significant decrease in M
strains (8.1 vs 2.9 %, P50.08). Year-by-year analysis of
phenotype prevalence revealed significant differences in
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the percentages of MLS isolates in the first 3 years of the
study: 2000 versus 2001 (30.4 vs 17.2 %, Pv0.0006) and
2001 versus 2002 (17.2 vs 5.9 %, Pv0.0001). By contrast,
a significant increase in M phenotype prevalence was
only noted between 2008 (12.3 %) and 2007 (6 %,
Pv0.023), as well as 2009 (4.4 %, Pv0.009).
To overcome the possible bias of annual blip variations,
statistical analysis was performed grouping chemosuscept-
ibility data by year: MLS phenotype percentage trends were
in full agreement with the erythromycin resistance trend
(Table 1).
Macrolide resistance genotypes
Out of 265 isolates that underwent further genetic analysis,
125 showed an MLS phenotype and 140 an M phenotype.
Of the latter, 139 carried the mefA gene and one the mefE
gene. Of the 125 MLS strains, 67 were iMLS and 58 cMLS
phenotypes. All iMLS strains were positive for the ermTR
gene; of these, seven isolates also carried the ermB gene,
and one was positive for ermTR and mefA. All cMLS iso-
lates were positive for ermB, three of which also carried
ermTR.
PFGE assays
Genetic relationships between isolates were evaluated by
PFGE. All but six isolates were digested by Cfr9I; these
six showed an M phenotype and were isolated in 2009. Sur-
prisingly, these six isolates were efficiently digested by
Sma I enzyme. Five isolates showed an identical pattern
and the other differed in two bands.
Analysis of PFGE patterns revealed 18 clones among the M-
phenotype isolates and 12 clones among the MLS-pheno-
type isolates. M-phenotype strains were more often geneti-
cally related than MLS strains (Figs. 2 and 3). Three major T
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Fig. 1. Year-by-year temporal trends (%) of total erythromycin
resistance and of the different phenotypes identified in the 2744
isolates of S. pyogenes.
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clones of M-phenotype isolates were observed in 2008,
coinciding with the previously described peak; in one of
these clones, seven isolates from 2008 were genetically
indistinguishable from seven isolates of 2007 (Fig. 4).
Remarkable genetic heterogeneity was found among isolates
of the years 2002–2003 (Fig. S1, available in the online Sup-
plementary Material), whereas in 2000 and 2007–2008,
clonal groups mainly consisted of MLS and M phenotypes,
respectively (Figs. 4 and 5). In particular, some genetically
related M strains persisted in the last two years of the
study. None of the resistant clones from 2000, 2002 and
2003 persisted during the period 2007–2008.
Susceptible isolates were not usually related to macrolide-
resistant strains, except for one isolate recovered in 2000,
which had an identical PFGE profile to an isolate with an
MLS phenotype, and two susceptible isolates recovered in
2002 with a PFGE profile identical to M-phenotype isolates.
emm typing
Overall, nine emm types were detected among the resistant
clones. The most frequent emm types were emm2, emm75,
emm77, emm12 and emm4, which were all recovered from
larger clones (clones D and T of M-phenotype strains and
clone H of MLS-phenotype strains) or were more frequent
among the isolates analysed. Four different additional emm
types (emm1, emm11, emm42 and emm89) were also recov-
ered sporadically. All but two isolates belonging to emm
type 75 and all isolates of emm2 and emm4 showed an M
phenotype, whereas all emm77 type isolates belonged to
the iMLS phenotype subpopulation. By contrast, suscep-
tible isolates showed several emm types, four of which
were common to resistant strains (emm1, emm2, emm12
and emm75). The complete genotypic data of isolates that
underwent emm typing are shown in Figs. 2 and 3 next
to the isolate code.
DISCUSSION
Macrolide resistance has spread in all parts of the world,
with wide geographical and temporal variations (Bingen
et al., 2000; Cresti et al., 2002; d’Humie`res et al., 2012;
Grivea et al., 2006; Huang et al., 2014; Montes et al.,
2014; Pe´rez-Trallero et al., 2007). The employment of
macrolides as empiric anti-streptococcal therapy must
therefore rely on basic resistance epidemiology data,
which is lacking in European countries. In general, our
findings revealed a lower rate of erythromycin resistance
in S. pyogenes isolates than in previous Italian observations
(Cornaglia et al., 1998), with a significant decrease during
our 14-year study period. The highest erythromycin
resistance rate, detected in the year 2000, matches a pre-
vious observation in our area in the 1990s (Cresti et al.,
2002). It was, however, followed by a significant decrease.
Our current chemosusceptiblity data are consistent with
recent observations in the USA (Villasen˜or-Sierra et al.,
2012), other European countries (d’Humie`res et al., 2012;
Montes et al., 2014) and recently, Italy (Gherardi et al.,
2015). A significant decrease in MLS isolates was observed,
from over 30 % in 2000 to 8 % since 2007; moreover, only
a few cMLS phenotype isolates were observed each year.
Such a low prevalence of isolates with high-level resistance
to all classes of macrolides, lincosamides and streptogramin
B may be favourable for the empirical treatment of severe
diseases, where clindamycin plays a major role (e.g. necro-
tizing fasciitis and streptococcal toxin shock syndrome)
(Bisno & Stevens, 2007). In contrast, we did not observe
major variations in the percentages of M-phenotype iso-
lates; apart from sporadic peaks (‘blips’), the M phenotype
only seemed to contribute in a minor way to the overall
erythromycin resistance trend in the study period.
The presence of known genetic resistance determinants was
verified in all erythromycin-resistant isolates: ermTR was
confirmed to be responsible for the iMLS phenotype (Var-
aldo et al., 2009); the coexistence of two erm alleles (ermB/
ermTR) was found in 5.6 % of all MLS isolates, although
only one was phenotypically expressed, as reported pre-
viously in streptococcal and pneumococcal isolates (Cas-
cone et al., 2002; de la Pedrosa et al., 2008; Giovanetti
et al., 2012; Silva-Costa et al., 2008). In our study, certain
emm types were specifically recovered among erythromy-
cin-resistant isolates, and were associated with different
phenotypes: emm75, emm2 and emm4 with an M pheno-
type and emm77 with an iMLS phenotype. These findings
are consistent with previous Italian reports (Creti et al.,
2005; Gherardi et al., 2015; Lorino et al., 2006; Zampaloni
et al., 2003).
Genetic and environmental factors can contribute to the
spread of antibiotic resistance: horizontal transfer of resist-
ance determinants and clonal expansion of resistant isolates
often act in synergy; in this context, selective pressure caused
by the use of different antibiotics can contribute to the
phenomenon (Albrich et al., 2004). Although our study
lacks data on macrolide use during the study period, a pre-
vious report from our area (Montagnani et al., 2009)
revealed the absence of a significant correlation between
local erythromycin resistance and overall consumption of
macrolides but a significant correlation between resistance
rates and a long-acting macrolide antibiotic (azithromycin).
Hence, clonal analysis is a powerful tool for understanding
epidemiological and temporal evolution of antibiotic resist-
ance. In our data, PFGE analysis revealed substantial
Fig. 2. Genetic relationships evaluated by PFGE in MLS phenotypes of S. pyogenes. Isolates in grey belong to clones sub-
jected to emm typing. Clones marked with * were no longer available for emm typing analysis.
R. Olivieri and others
1190 Journal of Medical Microbiology 64
Downloaded from www.microbiologyresearch.org by
IP:  193.205.6.111
On: Tue, 28 May 2019 15:25:48
36D18 M 03 
A
Population 3 of GAS - UPGMA, Dice coefficient
0.16 0.40 0.60 0.80 1.00
PF
G
E 
cl
us
te
r
em
m
 ty
pe
em
m
 c
lu
st
er
M
ac
ro
lid
e 
R 
ge
ne
s
B
C
2 E4
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
mefA
E14
75 E6
D 2 E4
E
F
G
H
12
12
75 E6
I
L
M
N
75
4
75
1
E6
E1
E6
AC3
O 42 E6
P
Q
R
S
T
75
75
2
2
E6
E6
E4
E4
2 E4
4
4
E1
E1
AC4
AC4
32B65 M 02
33A06 M 02
32A49 M 02
27C79 M 00
36D36 M 03
32D14 M 02
42B57 M 07
32D35 M 02
42D31 M 07
33D80 M 02
33D77 M 02
31D36 M 02
31D18 M 02
43A54 M 07
42D78 M 07
37A21 M 07
44A09 M 08
42B43 M 07
33B62 M 02
37A16 M 03
36D52 M 03
26B77 M 00
26C17 M 00
42D52 M 07
35D70 M 03
36D68 M 03
25C44 M 00
25C61 M 00
44A36 M 08
32B14 M 02
33B77 M 02
44A27 M 08
44B69 M 08
44B62 M 08
44A40 M 08
44B06 M 08
44A19 M 08
44A20 M 08
33B42 M 02
33B61 M 02
35A14 M 03
32B8 M 02
32A19 M 02
35C56 M 03
33A69 M 02
27C45 M 00
35C20 M 03
43E44 M 08
43A77 M 07
34C69 M 02
35D76 M 03
37B27 M 03
35B36 M 03
36D69 M 03
26B10 M 00
35A03 M 03
34C55 M 02
34C52 M 02
34C66 M 02
34C51 M 02
35C73 M 03
35C69 M 03
26C71 M 00
26C69 M 00
43C26 M 07
43B68 M 07
43B60 M 07
35C11 M 03
35C25 M 03
35C68 M 03
36C21 M 03
36C16 M 03
36A59 M 03
36B75 M 03
36B57 M 03
36C01 M 03
36B53 M 03
36A07 M 03
35A42 M 03
35A24 M 03
35D64 M 03
35D23 M 03
35A73 M 03
35A48 M 03
35A45 M 03
33D04 M 02
32D81 M 02
36A72 M 03
32B75 M 02
45A65 M 08
44D13 M 08
44C71 M 08
44B71 M 08
37B35 M 03
37B34 M 03
37A56 M 03
32A79 M 03
32A77 M 02
32A76 M 02
45B12 M 08
45B04 M 08
43C77 M 07
43C18 M 07
43B52 M 07
43B47 M 07
45A67 M 08
44C72 M 08
44C45 M 08
44B08 M 08
43E47 M 08
43E05 M 07
43D22 M 07
43D05 M 07
35C58 M 03
43E80 M 08
36D40 M 02
31C67 M 02
Fig. 3. Genetic relationships evaluated by PFGE in M phenotypes of S. pyogenes. Isolates in grey belong to clones subjected
to emm typing.
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diffusion of genetically relatedMLS isolates in the first year of
the study, when the prevalence of erythromycin resistance
was highest; moreover, none of the genetically related resist-
ant strains in 2000–2003 persisted in 2007–2008, when
mainly genetically related M-phenotype isolates were
found. Interestingly, a prevalence ofMoverMLS phenotypes
was reported recently in European and non-European
countries, with a similar decrease in erythromycin resistance
rates (Huang et al., 2014; Montes et al., 2014).
Susceptible isolates revealed several emm types, partially
shared with resistant ones.
According to our data, changes in bacterial population
clonality, rather than horizontal transfer of resistance
determinants, could play a major role in temporal vari-
ations in the prevalence of erythromycin resistance. A few
successful clones seemed mainly associated with the
spread of resistance in certain years, in line with similar
epidemiological reports from other areas of Italy (Gherardi
et al., 2015; Zampaloni et al., 2003). Data on macrolide
consumption in our area during the study period is lack-
ing, but, as antibiotic selective pressure may contribute to
clonal expansion phenomena and long-acting macrolides
can have a selective influence (Montagnani et al., 2009),
our microbiological observations suggest that changes in
specific antibiotic selection pressure at the community
level could be the main driver of the observed reduction
in macrolide resistance. This encourages the implemen-
tation of antibiotic stewardship programme aimed at con-
tainment of the worldwide spread of macrolide resistance.
Regarding a possible bias of our study, we clarify that com-
plete microbiological characterization of isolates (e.g. by
multilocus sequence typing) was beyond the scope of our
research, which was mainly aimed at supporting empirical
therapeutic management of streptococcal infections. The
observed temporal and geographical variations in chemosus-
ceptibility rates suggested that continuous monitoring of
microbiological epidemiology is indeed pivotal for correct
and effective clinical management of streptococcal infections.
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